Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in acute decompensated heart failure
NL-OMON46516Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Acute Heart Failure (AHF) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Dyspnea relief, Diuretic response and 2 more. Started Jan 2018; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
Acute Heart Failure (AHF)
Beyond the preview
Go deeper on NL-OMON46516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46516.